SNCA and synucleinopathy: The potential of the candidate vaccines to stimulate an immune response in mice could pave the way for the development of an effective immunotherapy for PD and other synucleinopathies as they were engineered to mimic the amyloid fibril structure of alpha‐synuclein, the misfolded protein implicated in the pathogenesis of these neurodegenerative disorders.